3 Stocks Pushing The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 30 points (0.2%) at 15,994 as of Thursday, Feb. 13, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,823 issues advancing vs. 1,044 declining with 196 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is up 0.2%. A company within the industry that fell today was Regeneron Pharmaceuticals ( REGN), up 0.5%. Top gainers within the industry include Pacira Pharmaceuticals ( PCRX), up 11.3%, Celgene Corporation ( CELG), up 2.0%, AstraZeneca ( AZN), up 1.6%, Biogen Idec ( BIIB), up 0.8% and Allergan ( AGN), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Dr. Reddy Laboratories ( RDY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Dr. Reddy Laboratories is down $0.98 (-2.3%) to $41.74 on average volume. Thus far, 98,799 shares of Dr. Reddy Laboratories exchanged hands as compared to its average daily volume of 198,300 shares. The stock has ranged in price between $41.08-$41.89 after having opened the day at $41.28 as compared to the previous trading day's close of $42.72.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Dr. Reddy Laboratories has a market cap of $7.3 billion and is part of the health care sector. Shares are up 4.1% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Dr. Reddy Laboratories a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Dr. Reddy Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Dr. Reddy Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Medicines ( MDCO) is down $4.87 (-14.7%) to $28.23 on heavy volume. Thus far, 2.8 million shares of Medicines exchanged hands as compared to its average daily volume of 772,500 shares. The stock has ranged in price between $28.14-$29.18 after having opened the day at $28.95 as compared to the previous trading day's close of $33.10.

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. Medicines has a market cap of $2.1 billion and is part of the health care sector. Shares are down 14.3% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Medicines a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Medicines as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full Medicines Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Incyte ( INCY) is down $2.83 (-4.1%) to $66.00 on heavy volume. Thus far, 1.9 million shares of Incyte exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $65.34-$68.17 after having opened the day at $66.50 as compared to the previous trading day's close of $68.83.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $10.6 billion and is part of the health care sector. Shares are up 36.0% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk. Get the full Incyte Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Changing Landscape for Generic-Drug Makers Creates Opportunities

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume